MARSHALL & POPP, LLC

Lobbying for DAIICHI SANKYO, INC. · Biopharmaceutical manufacturer.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · posted Apr 17, 2026

Lobbying activity 1

Pharmacy

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.